Zarabozo C
Office of Strategic Planning, Health Care Financing Administration, Washington, DC 20201, USA.
Health Care Financ Rev. 1999 Spring;20(3):1-13.
This overview ties together the various articles by relating them to the current debate on whether, and how, the Medicare program can add outpatient drugs as a covered benefit. The unifying theme for most of the articles is that they outline possible ways of administering a drug benefit and discuss policy issues that will arise, based on Health Care Financing Administration (HCFA) experiences or State government experiences in efforts to administer existing drug benefits in a cost-effective manner while attempting to ensure the best medical outcomes. The articles provide information about drug utilization among Medicare beneficiaries with and without insurance coverage, among Medicaid beneficiaries, and among subpopulations for whom drug therapies can be considered essential.
本综述通过将各种文章与当前关于医疗保险计划是否以及如何将门诊药物作为承保福利的辩论联系起来，把它们整合在一起。大多数文章的统一主题是，它们概述了实施药物福利的可能方式，并根据医疗保健财务管理局（HCFA）的经验或州政府在以具有成本效益的方式管理现有药物福利同时努力确保最佳医疗结果方面的经验，讨论将会出现的政策问题。这些文章提供了有关有保险和无保险的医疗保险受益人群、医疗补助受益人群以及药物治疗可被视为必不可少的亚人群的药物使用情况的信息。
